NCT04218981View on ClinicalTrials.gov

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

NACompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

June 25, 2023

Study Completion Date

December 31, 2023

Conditions

Common Mental Disorder

Interventions

DRUG

Antipsychotic drugs

Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group

DRUG

Mood stabilizer

Choose lithium or valproate for bipolar disorder group

DRUG

Paroxetine

Patients with major depressive disorder are treated with paroxetine

Trial Locations (1)

Unknown

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

Central South University

OTHER

NCT04218981 - Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders | Biotech Hunter | Biotech Hunter